ClinicalTrials.gg

TargetBeta

TLR8

toll like receptor 8 · also CD288, hTLR8 · CD molecules

4 programs in company-led studies act on TLR8, from 4 companies: 3 in phase 3. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (3 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
resiquimodruleStaidson (Beijing) Biopharmaceuticalsphase 3144 runningTLR7ChEMBL
enpatoranruleMerck KGaA, Darmstadt, Germanyphase 3124 runningTLR7ChEMBL
afimetoranruleBristol-Myers Squibbphase 3122 runningTLR7ChEMBL
TQA3810Sino Biopharmaceuticalphase 221 running–the company's pipeline

Also acted on by the same programs

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.